###begin article-title 0
Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells
###end article-title 0
###begin p 1
###xml 147 173 147 173 <email xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">kristi.anseth@colorado.edu</email>
Correspondence: University of Colorado, Department of Chemical and Biological Engineering, ECCH 111, UCB 424, Boulder, CO 80309-0424, USA. E-mail: kristi.anseth@colorado.edu
###end p 1
###begin p 2
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
This study aimed to identify signaling pathways that oppose connective tissue fibrosis in the aortic valve. Using valvular interstitial cells (VICs) isolated from porcine aortic valve leaflets, we show that basic fibroblast growth factor (FGF-2) effectively blocks transforming growth factor-beta1 (TGF-beta1)-mediated myofibroblast activation. FGF-2 prevents the induction of alpha-smooth muscle actin (alphaSMA) expression and the exit of VICs from the cell cycle, both of which are hallmarks of myofibroblast activation. By blocking the activity of the Smad transcription factors that serve as the downstream nuclear effectors of TGF-beta1, FGF-2 treatment inhibits fibrosis in VICs. Using an exogenous Smad-responsive transcriptional promoter reporter, we show that Smad activity is repressed by FGF-2, likely an effect of the fact that FGF-2 treatment prevents the nuclear localization of Smads in these cells. This appears to be a direct effect of FGF signaling through mitogen-activated protein kinase (MAPK) cascades as the treatment of VICs with the MAPK/extracellular regulated kinase (MEK) inhibitor U0126 acted to induce fibrosis and blocked the ability of FGF-2 to inhibit TGF-beta1 signaling. Furthermore, FGF-2 treatment of VICs blocks the development of pathological contractile and calcifying phenotypes, suggesting that these pathways may be utilized in the engineering of effective treatments for valvular disease.-Cushing, M. C., Mariner, P. D., Liao, J. T., Sims, E. A., Anseth, K. S. Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells.
###end p 3
###begin p 4
###xml 0 27 0 27 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Valvular interstitial cells</sc>
###xml 194 197 194 197 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
###xml 440 442 440 442 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">(2</xref>
###xml 442 446 442 446 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">, 3)</xref>
###xml 567 570 567 570 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">(4)</xref>
###xml 619 622 619 622 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">(5)</xref>
###xml 877 880 877 880 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">(6)</xref>
###xml 1059 1061 1059 1061 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">(7</xref>
###xml 1061 1062 1061 1062 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
###xml 1062 1064 1062 1064 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">9)</xref>
###xml 231 243 <span type="species:ncbi:9606">participants</span>
Valvular interstitial cells (VICs) are the main cell type of the cardiac valve leaflet and constitute a phenotypically dynamic population of cells that can be activated to become myofibroblasts (1). Although myofibroblasts are key participants in wound repair and tissue remodeling, improper regulation of VIC myofibroblast activation can have deleterious effects in heart valves, including excessive scarring and calcific nodule formation (2, 3). For this reason, the life cycle of the VIC is carefully regulated such that activated myofibroblasts undergo apoptosis (4) and/or revert back to a quiescent VIC phenotype (5) when wound healing is completed. Under pathological conditions, prolonged myofibroblast activation leads to an accumulation of compositionally unbalanced extracellular matrix (ECM) that alters the mechanical and hemodynamic properties of the heart valve (6). Similar effects have been observed in other tissues, where the chronic persistence of ECM-producing myofibroblast cells has been linked to deposition of collagenous scar tissue (789). For this reason, an understanding of the signaling mechanisms that control VIC differentiation in the heart valve is critical to our ability to prevent valvular fibrosis and dysfunction.
###end p 4
###begin p 5
###xml 113 117 113 117 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">(10)</xref>
###xml 134 137 134 137 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
###xml 158 161 158 161 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">(11</xref>
###xml 161 166 161 166 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">, 12)</xref>
###xml 177 185 177 185 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 486 488 474 476 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">(3</xref>
###xml 488 492 476 480 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">, 13</xref>
###xml 492 497 480 485 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">, 14)</xref>
###xml 526 529 514 517 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">(3)</xref>
###xml 744 747 729 732 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">(15</xref>
###xml 747 752 732 737 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B16" ref-type="bibr">, 16)</xref>
###xml 944 951 926 933 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">de novo</italic>
###xml 1028 1030 1002 1004 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1</xref>
###xml 1030 1035 1004 1009 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B17" ref-type="bibr">, 17)</xref>
Myofibroblast differentiation in the heart can be induced by several mechanisms, including exposure to cytokines (10), growth factors (1), and ECM components (11, 12). Cultured in vitro, VICs isolated from porcine heart valves can be stimulated to become myofibroblasts with transforming growth factor-beta1 (TGF-beta1). TGF-beta is one of the most widely distributed profibrotic cytokines, and disruption of TGF-beta homeostasis has been linked to enhanced fibrogenesis in many organs (3, 13, 14), including the aortic valve (3). TGF-beta regulates the deposition of ECM in both normal responses to tissue injury and in pathological settings and has been shown to skew the composition of neomatrix toward predominantly collagenous scar tissue (15, 16). The addition of exogenous TGF-beta1 to VIC cultures leads to myofibroblast activation, as observed by increased ECM and cytokine secretion, as well as enhanced contractility mediated by the de novo expression of alpha-smooth muscle actin (alphaSMA)-containing stress fibers (1, 17). Although much is known about the deleterious effects of chronic TGF-beta signaling, little is known about the pathways that work in opposition to TGF-beta-mediated pathological fibrosis and keep myofibroblast activation in check.
###end p 5
###begin p 6
###xml 146 150 146 150 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">(18)</xref>
###xml 177 180 177 180 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">(7)</xref>
###xml 202 206 202 206 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">(19)</xref>
###xml 233 237 233 237 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">(20)</xref>
###xml 585 589 585 589 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">(21)</xref>
In several other tissues, basic fibroblast growth factor (FGF-2) has been shown to diminish the activation of myofibroblasts. In retinal pericyte (18), breast gland fibroblasts (7), corneal fibroblasts (19), and synovial fibroblasts (20), FGF-2 appears to play an important role in proper wound- healing responses and may act to prevent the deleterious effects of persistent myofibroblast activation. Recently, it was shown that fibroblasts with reduced FGF receptor (FGF-R) expression spontaneously differentiated to myofibroblasts, presumably as a result of impaired FGF-2 signaling (21). These reports suggest that FGF-2 acts as a general antifibrotic factor that can counteract the profibrotic activity of TGF-beta1, leading us to hypothesize that FGF-2 plays a similar role in valvular interstitial cells.
###end p 6
###begin p 7
###xml 252 256 246 250 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">(15)</xref>
###xml 923 926 911 914 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">(22</xref>
###xml 926 931 914 919 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">, 23)</xref>
In this study, we show that FGF-2 acts to reduce TGF-beta1-mediated myofibroblast activation of VICs by preventing the nuclear translocation of Smad transcription factors. TGF-beta1 signals through serine/threonine receptor kinases to activate R-Smads (15). Once activated, these Smads are shuttled to the nucleus where they induce the expression of multiple gene targets. Nucleo-cytoplasmic shuttling of Smads can be blocked, however, by other signaling pathways that act in opposition to Smad-mediated fibrosis. In VICs, we show that FGF-2 treatment blocks the nuclear localization of Smads and leads to a reduction in phenotypic markers that are typical of myofibrotic activation. This effect appears to be mediated by mitogen-activated protein kinases (MAPKs), which have been shown previously to antagonize TGF-beta signaling by repressing TGF-beta receptor expression and attenuating Smad accumulation in the nucleus (22, 23).
###end p 7
###begin p 8
The identification of an FGF-2-mediated pathway that opposes myofibroblast activation in VICs has immediate implications for the prevention and treatment of valvular disease. We demonstrate that FGF-2 not only inhibits TGF-beta-mediated myofibroblast activation but that it also prevents calcified nodule formation and matrix contraction in VICs. These phenotypes are both characteristic of end-stage valvular disease, suggesting that the maintenance of FGF-2-mediated pathways is an important aspect to preventing the progression of deleterious fibrosis in heart valves.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
Cell Culture
###end title 10
###begin p 11
###xml 106 110 106 110 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B24" ref-type="bibr">(24)</xref>
###xml 365 368 365 368 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
###xml 1050 1051 1037 1038 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">,</sub>
###xml 390 396 <span type="species:ncbi:9913">bovine</span>
###xml 957 962 <span type="species:ncbi:10090">Mouse</span>
###xml 1052 1056 <span type="species:ncbi:9925">goat</span>
###xml 1062 1067 <span type="species:ncbi:10090">mouse</span>
###xml 1087 1098 <span type="species:ncbi:3704">horseradish</span>
VICs were isolated by sequential collagenase digestion of porcine aortic leaflets as described previously (24). Briefly, aortic leaflets were removed from intact porcine hearts (Hormel, Austin, MN, USA) and subjected to sequential collagenase digestion (250 U/ml, Worthington Biochemical, Lakewood, NJ, USA). Isolated cells were plated and cultured in growth media (1) containing 15% fetal bovine serum (FBS) and allowed to expand until reaching near confluency before freezing and storage at 80degreesC. As needed, VICs were thawed and taken through two passages before use in these experiments. Cell treatments were added 12 h after cell seeding for a period of 48 h. Recombinant porcine TGF-beta1 was purchased from R&D Systems (Minneapolis, MN, USA). Monoclonal antibodies anti-FGF-2, anti-FGFR-2, anti-FGFR-3, as well as the growth factors FGF-2, were purchased from Sigma (St. Louis, MO, USA). U0126 was purchased from Calbiochem (La Jolla, CA, USA). Mouse monoclonal anti-alphaSMA was purchased from Abcam (Cambridge, MA, USA). Alexa Fluor 488, goat anti-mouse IgG (GAM-488), GAM-horseradish perioxidase (HRP), and GAR-HRP were purchased from Molecular Probes (Eugene, OR, USA). Unless otherwise stated, all other chemicals were purchased from Sigma-Aldrich.
###end p 11
###begin title 12
Cell-based fluorometric enzyme-linked immunosorbent assay
###end title 12
###begin p 13
###xml 121 125 117 121 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">(25)</xref>
###xml 343 344 335 336 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 619 620 607 608 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 633 634 621 622 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 635 636 623 624 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1164 1165 1148 1149 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1493 1495 1477 1479 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 652 658 <span type="species:ncbi:9913">bovine</span>
Quantification of alphaSMA expression by enzyme-linked immunosorbent assay (ELISA) was performed as described previously (25). This assay was further modified to allow for semiquantitative labeling of alphaSMA normalized to DNA in every sample repeat. Seeding was performed in black tissue-culture 96-well flat-bottom plates at 15,000 cells/cm2 for alphaSMA expression assays. After 48 h of treatment with media containing growth factors or inhibitors, cells were fixed with 10% buffered formalin, washed in phosphate buffered saline containing (PBS) 0.05% Tween-20, quenched of endogenous peroxidases with 0.1 wt % NaN3 and 0.3 mM H2O2, blocked in 3% bovine serum albumin, and incubated with anti-alphaSMA primary and GAM-HRP secondary antibodies. In corresponding controls, specific staining was confirmed by inverted fluorescent microscopy (GAM-488 secondary) after counterstaining nucleic acids with propidium iodide (500 nmol/L; Eclipse TE300; Nikon, Tokyo, Japan). Fluorogenic HRP-substrate QuantaBlu (Pierce, Rockford, IL, USA) was incubated with HRP-labeled samples, and the development of fluorescence was measured by automated plate reader (Wallac Victor2 Multilabel Counter, PerkinElmer, Waltham, MA, USA) and normalized to a negative control with no primary antibody. The same samples were then digested with papain protease (Worthington Biochemical) for subsequent quantification of DNA content with the PicoGreen dsDNA assay and lambda DNA standard curve (Molecular Probes; ref. 25). For each well, QuantaBlu fluorescence was normalized to DNA content, as determined by PicoGreen dsDNA assay (Invitrogen, Carlsbad, CA, USA), to indicate protein expression per cell with the assumption that that each cell contained equal quantities of DNA.
###end p 13
###begin title 14
ECM production
###end title 14
###begin p 15
###xml 33 34 33 34 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 101 105 101 105 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B26" ref-type="bibr">(26)</xref>
###xml 269 270 269 270 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
ECM production was evaluated by [3H]proline incorporation over a 96 h period as described previously (26). Briefly, cells were removed from culture after treatment and extensively washed in PBS, and cell-associated proline was removed with a cell lysis step in 25 mM NH4OH to remove cytosolic proteins. Remaining ECM was then digested for 4 h with papain protease at 37degreesC. Digests were combined with scintillation fluid, and radioactivity was determined by scintigraphy (Beckman LS 6500, Beckman Instruments, Fullerton, CA, USA). DNA from corresponding samples was quantified using the PicoGreen dsDNA assay after cell lysis in GloLysis Buffer (Promega, Madison, WI, USA). Data are presented as the counts per minute normalized to DNA content.
###end p 15
###begin title 16
Transfections and Smad-reporter systems
###end title 16
###begin p 17
###xml 197 201 197 201 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B27" ref-type="bibr">(27)</xref>
The Smad-3 luciferase reporter PE2.1 was a generous gift of Dr. Xuedong Liu (University of Colorado, Boulder, CO, USA) and contains three Smad binding elements driving the expression of luciferase (27). VICs were transfected using a 1:2 ratio of plasmid:Lipofectamine 2000 in Opti-Mem (Invitrogen) and stimulated with growth factors for 48 h before assay. Luciferase activity was assayed using the Bright-Glo luciferase assay system (Promega) as per the manufacturer's instructions.
###end p 17
###begin title 18
Valve leaflet organ culture and preparation
###end title 18
###begin p 19
###xml 93 97 93 97 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B24" ref-type="bibr">(24)</xref>
Porcine aortic leaflets were removed from intact hearts as done for VIC isolation procedures (24). Instead of subjecting the leaflets to collagenase digestion, however, the dissected tissue was cut into constructs measuring 0.7 cm per side with native valve thickness and cultured in 24-well untreated plates with VIC growth media. Plates were placed on an orbital shaker at 65 rpm in a tissue culture incubator. Leaflets were removed from culture, fixed, paraffin-embedded, and sectioned at 4 mum intervals. Sections were deparaffinized using graded ethanol washes and xylene, and immunostained for alphaSMA using the avidin-biotin amplification complex (immunoperoxidase ABC technique) in conjunction with the NovaRED peroxidase substrate (Vector Labs, Burlingame, CA, USA).
###end p 19
###begin title 20
Collagen gel contraction assays
###end title 20
###begin p 21
###xml 379 380 370 371 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 834 838 824 828 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B28" ref-type="bibr">(28)</xref>
Chilled collagen (PureCol, INAMED, Burlington, Ontario, Canada) was combined with 10x Medium 199 (Invitrogen) and 0.1M NaOH in a ratio of 8:1:1, added to the VIC cell pellet (150,000 cell/gel), and adjusted to a pH of 7.4 +/- 0.2 with 0.1 M NaOH. The resulting homogenous solution was immediately aliquoted into 48-well plates (300 mul/well) and incubated at 37degreesC and 5% CO2 for a minimum of 60 min. After gelation, 500 mul of conditioned media was added to each well. After 24 h, the gels were gently detached from the plates with a thin spatula, and digital images of floating collagen constructs were taken with a high-resolution scanner. The collagen gel area was measured using ImageJ software [National Institutes of Health (NIH), Bethesda, MD, USA], and macroscopic changes in gel area for each condition were determined (28).
###end p 21
###begin title 22
Calcific nodule formation
###end title 22
###begin p 23
###xml 36 37 36 37 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 318 322 318 322 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B29" ref-type="bibr">(29)</xref>
Cells were seeded at 30,000 cells/cm2 in a clear 96-well plate and treated for 72 h. The cells were then fixed overnight in 10% buffered formalin, stained with 2% Alizarin Red (Fisher Scientific, Pittsburgh, PA, USA) solution, and thoroughly washed in PBS. Calcific nodules were visually identified and counted at x10 (29).
###end p 23
###begin title 24
RESULTS
###end title 24
###begin title 25
FGF-2 reduces basal markers of myofibroblast activation in VIC cultures
###end title 25
###begin p 26
###xml 68 75 68 75 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 75 79 75 79 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B30" ref-type="bibr">(30)</xref>
###xml 181 187 177 183 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1</bold>
###xml 181 187 177 183 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig"><bold>Fig. 1</bold></xref>
###xml 448 452 436 440 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">(31)</xref>
###xml 724 731 708 715 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">AIII&#8211;IV</italic>
###xml 718 731 702 715 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">Fig. 1<italic>AIII&#8211;IV</italic></xref>
###xml 789 793 773 777 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">AIII</italic>
###xml 783 793 767 777 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">Fig. 1<italic>AIII</italic></xref>
###xml 826 829 810 813 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">AIV</italic>
###xml 820 829 804 813 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">Fig. 1<italic>AIV</italic></xref>
###xml 865 867 849 851 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">AV</italic>
###xml 859 867 843 851 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">Fig. 1<italic>AV</italic></xref>
Because FGF-2 has been investigated for its antifibrotic properties in vivo(30), we examined the effects of FGF-2 treatment on alphaSMA expression in cultured VICs. As presented in Fig. 1AI, II, VICs treated with 10 ng/ml FGF-2 showed reduced staining for alphaSMA expression (green) when compared with untreated controls. Expression of alphaSMA is a fundamental feature of activated myofibroblasts and serves as a key marker of fibrotic responses (31). Furthermore, blocking even basal levels of FGF signaling that result from FGF found in FBS, as well as from autocrine-mediated activation of FGF receptors, successfully induced alphaSMA expression, consistent with a fibrotic response in cultured VICs. As shown in Fig. 1AIII-IV, the addition of antibodies that neutralize FGF-2 (Fig. 1AIII), FGF receptor-2 (FGFR-2; Fig. 1AIV), or FGF receptor-3 (FGFR-3; Fig. 1AV) significantly increased alphaSMA expression, suggesting that even low levels of FGF signaling are present in VIC cultures and that this acts to keep these cells in an undifferentiated, nonfibrotic state.
###end p 26
###begin p 27
###xml 198 199 198 199 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 192 199 192 199 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 381 382 375 376 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 411 417 405 411 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 2</bold>
###xml 411 417 405 411 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig"><bold>Fig. 2</bold></xref>
###xml 503 507 497 501 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 509 512 503 506 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">via</italic>
###xml 904 905 896 897 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 898 905 890 897 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">Fig. 1<italic>D</italic></xref>
To test the concentration range at which FGF-2 prevents fibrosis in VICs, cell were treated with increasing concentrations of FGF-2 and monitored for specific markers of fibrosis. As shown in Fig. 1B, concentrations of FGF-2 >/=10 ng/ml in the culture media caused a significant reduction in alphaSMA expression as measured by ELISA. Similarly, FGF-2 reduced the incorporation of [3H]proline into ECM proteins (Fig. 2C), indicating that the cells were not actively producing fibrotic connective tissue (e.g., via the deposition of proline-rich collagen). All concentrations of FGF-2 tested (>/=1 ng/ml) caused a significant reduction of matrix production per cell. Furthermore, this decrease in ECM production did not result from reduced cell proliferation, as the quantification of dsDNA suggests that cell numbers remained constant in FGF-2-treated samples when compared with untreated controls (Fig. 1D).
###end p 27
###begin title 28
FGF-2 blocks TGF-beta1-mediated myofibroblast activation
###end title 28
###begin p 29
###xml 297 300 290 293 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
###xml 320 321 313 314 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 314 321 307 314 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 776 777 752 753 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 770 777 746 753 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2<italic>B</italic></xref>
Given the ability of FGF-2 to reduce markers of fibrosis under normal culture conditions, we wanted to determine if FGF-2 could block activated myofibroblast differentiation. TGF-beta1 has been shown to induce alphaSMA expression, increase ECM deposition, and block cellular proliferation in VICs (1). As shown in Fig. 2A, treatment of VICs with TGF-beta1 (5 ng/ml for 48 h) markedly induced alphaSMA expression when compared with untreated controls (dashed line). The cotreatment of VICs with TGF-beta1 and increasing concentrations of FGF-2, however, prevented increases in alphaSMA expression, suggesting that myofibroblast activation is blocked by FGF-2. Similarly, treatment of VICs with FGF-2 effectively blocked TGF-beta1-mediated increases in matrix production (Fig. 2B). No significant difference was observed in the production of ECM proteins at concentrations >/=10 ng/ml FGF-2, suggesting that these cells had not been activated by TGF-beta1 and remained undifferentiated.
###end p 29
###begin p 30
###xml 106 107 106 107 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 100 107 100 107 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2<italic>C</italic></xref>
Additionally, cellular proliferation was restored in VICs that were treated with FGF-2. As shown in Fig. 2C, the treatment of VICs with TGF-beta1 resulted in a marked decrease in the quantity of dsDNA per well, suggesting that DNA synthesis and cellular proliferation were reduced compared with untreated cells (dashed line). TGF-beta1 removed cells from the cell cycle and effectively decreased cell numbers when compared with untreated controls. In contrast, cells that were also treated with FGF-2 had DNA quantities similar to untreated cells, suggesting that these cells were not induced to differentiate and that their normal cellular proliferation rates were maintained.
###end p 30
###begin p 31
###xml 479 487 472 480 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1)</xref>
###xml 662 663 655 656 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 656 663 649 656 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 948 956 937 945 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1)</xref>
These data suggest that the fine balance between FGF-mediated pathways and TGF-beta-mediated pathways is tipped in favor of FGF under normal culturing conditions with 15% FBS. Indeed, these conditions act to promote proliferation and are used to expand cell numbers. The presence of FGF signaling under normal culturing conditions is also demonstrated in previous experiments in which blocking FGF signaling with neutralizing antibodies resulted in increased alphaSMA expression (Fig. 1). Given this observation, we hypothesized that the removal of serum from these cells would reduce FGF signaling and result in myofibroblast differentiation. As shown in Fig. 2D, culturing VICs in serum-free conditions caused an increase in alphaSMA expression, consistent with a fibrotic response. Together, these data suggest that FGF is present in FBS and likely maintains VICs in an undifferentiated state. The cells remain responsive to FGF supplementation (Fig. 1), however, indicating that the level of FGF in FBS is not causing a maximal response.
###end p 31
###begin p 32
###xml 161 162 158 159 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 155 162 152 159 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 453 454 437 438 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 455 456 439 440 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 447 456 431 440 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2<italic>A</italic>&#8211;<italic>C</italic></xref>
FGF signaling does not appear to be acting unopposed under these conditions, however, and TGF-beta-mediated pathways also appear to be active. As shown in Fig. 2D, treatment of VICs with an anti-TGF-beta neutralizing antibody caused a decrease in alphaSMA expression, suggesting that TGF-beta signaling occurs under these conditions and acts to maintain a certain level of differentiation. The cells remain responsive to TGF-beta supplementation (Fig. 2A-C), however, indicating that the level of TGF-beta in FBS is not causing a maximal response. Together, these data suggest that the FGF- and TGF-beta-mediated pathways are both activated when VICs are cultured with 15% FBS but that FGF-mediated effects predominate.
###end p 32
###begin title 33
FGF-2 prevents TGF-beta1-mediated Smad activation
###end title 33
###begin p 34
###xml 402 406 396 400 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B32" ref-type="bibr">(32)</xref>
###xml 472 476 466 470 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B27" ref-type="bibr">(27)</xref>
###xml 584 590 575 581 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 3</bold>
###xml 584 590 575 581 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig"><bold>Fig. 3</bold></xref>
To identify the mechanism by which FGF-2 blocks TGF-beta1-mediated activation of VICs, we investigated the activity of Smad transcription factors in these cells. Both Smad-2 and Smad-3 are phosphorylated by TGF-beta type I receptors, causing them to become activated. Once activated, these Smads are translocated to the nucleus where they increase the expression of a variety of fibrosis-related genes (32). By transfecting VICs with the PE2.1 luciferase reporter plasmid (27), we tested the ability of FGF-2 to inhibit TGF-beta1-mediated Smad transcriptional activation. As shown in Fig. 3A, stimulation of transfected VICs with TGF-beta1 caused an induction of the Smad-binding luciferase reporter. This increase was blocked, however, when FGF-2 was codelivered with TGF-beta1, indicating that FGF-2 effectively blocked the transcriptional activity of Smads that are the downstream targets of TGF-beta1 signaling in these cells.
###end p 34
###begin p 35
###xml 310 311 310 311 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 304 311 304 311 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Fig. 3<italic>B</italic></xref>
Activated Smads require partnering with DNA-binding cofactors to regulate selective transcriptional activity of target genes in the nucleus, suggesting that FGF-2 either prevents Smad translocation to the nucleus or blocks the interaction of Smads with their binding partners in the nucleus. As shown in Fig. 3B, TGF-beta1-mediated translocation of Smad-3 to the nucleus was blocked by FGF-2. Smad-3 was clearly localized to the nucleus in cells treated with TGF-beta1 (45 min, 5 ng/ml), whereas Smad-3 was excluded from the nuclei of cells that were also treated with FGF-2. These results suggest that FGF-2 prevents fibrosis in VICs by interfering with TGF-beta1 signaling by blocking Smads from entering the nucleus to activate genes involved in myofibroblast differentiation.
###end p 35
###begin title 36
Inhibition of MAPK signaling prevents FGF-2 activity
###end title 36
###begin p 37
###xml 47 51 47 51 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B33" ref-type="bibr">(33)</xref>
###xml 419 425 416 422 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 4</bold>
###xml 419 425 416 422 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig"><bold>Fig. 4</bold></xref>
###xml 1264 1265 1249 1250 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1258 1265 1243 1250 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 1371 1372 1356 1357 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1365 1372 1350 1357 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1657 1658 1638 1639 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1651 1658 1632 1639 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1750 1753 1731 1734 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">via</italic>
Since FGF-2 is known to activate MAPK pathways (33), we hypothesized that blocking MAK kinase cascades would attenuate the antifibrotic activity of FGF-2 in VICs. By using the pharmacological MAPK/extracellular regulated kinase (ERK) (MEK)-1/2 inhibitor U0126 to block downstream FGF-2 signaling in VIC cultures, we successfully abrogated the ability of FGF-2 to interfere with TGF-beta1-mediated fibrosis. As shown in Fig. 4A, the addition of U0126 to the culture media caused an increase in the activity of the PE2.1 luciferase reporter, indicating that Smad-mediated signaling was increased as a result of MAPK inhibition. This effect is likely a result of an increase in the nuclear localization of Smad-3 in U0126-treated cells (data not shown). Furthermore, U0126 did not significantly alter TGF-beta1 activation of the PE2.1 reporter; instead, it prevented FGF-2 from interfering with Smad activation. The use of U0126 in combination with TGF-beta1 had little effect on the PE2.1 reporter activity in that luciferase activity under these conditions was not significantly different from the luciferase activity of cells treated with TGF-beta1 alone. As demonstrated earlier, FGF-2 effectively blocked this TGF-beta1-induced increase in PE2.1 activity (Fig. 3A); however, FGF-2 was unable to prevent the activation of the Smad reporter when U0126 was present (Fig. 4A), indicating that MEK-1/2 is involved in the FGF-2-mediated repression of Smad activity. These results are consistent with endogenous gene markers of fibrosis in that U0126 also significantly increased alphaSMA expression in VIC cultures, even when FGF-2 is added to the media (Fig. 4B). Together, these data suggest that FGF-2 acts to inhibit myofibroblast activation of VICs via MAPK-mediated inhibition of Smad signaling.
###end p 37
###begin title 38
FGF-2/MAPK signaling prevents fibrosis in intact aortic leaflets
###end title 38
###begin p 39
###xml 246 254 246 254 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 442 448 435 441 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 5</bold>
###xml 442 448 435 441 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig"><bold>Fig. 5</bold></xref>
###xml 634 635 623 624 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 628 635 617 624 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>I</italic></xref>
###xml 759 761 748 750 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">II</italic>
###xml 753 761 742 750 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>II</italic></xref>
###xml 816 819 802 805 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">III</italic>
###xml 810 819 796 805 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>III</italic></xref>
###xml 837 839 823 825 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IV</italic>
###xml 831 839 817 825 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>IV</italic></xref>
###xml 1037 1038 1019 1020 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 1031 1038 1013 1020 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>V</italic></xref>
To validate our culture system and evaluate the effects of FGF-2 and MAPK blockade on VICs within their native ECM architecture, valve leaflet organ culture was performed. Aortic leaflets were surgically isolated from porcine hearts and cultured in vitro with TGF-beta1, FGF-2, U0126, or FGF-2 combined with U0126. alphaSMA expression was monitored after 2 wk of treatment by histological sectioning, and representative leaflets are shown in Fig. 5. In control constructs, treated only with serum-containing growth media, there was evidence of small clusters of alphaSMA-positive cells, particularly near the leaflet free edge (Fig. 5I). FGF-2-treated cultures also had low levels of diffuse positive staining uniformly throughout the leaflet interior (Fig. 5II). In contrast, leaflets treated with TGF-beta1 (Fig. 5III) or U0126 (Fig. 5IV) had enhanced foci of positive staining, where treatment formed bands or clusters of activated cells. Additionally, alphaSMA staining remained elevated when FGF-2 and U0126 were codelivered (Fig. 5V). These clusters may represent the early stages of nodule formation and demonstrate the importance of FGF-2 and MAPK signaling in preventing fibrosis in the aortic valve.
###end p 39
###begin title 40
FGF-2 prevents TGF-beta1-mediated contraction and pathological node formation
###end title 40
###begin p 41
###xml 110 113 107 110 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">(3)</xref>
###xml 115 123 112 120 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 263 266 257 260 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
###xml 356 362 350 356 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 6</bold>
###xml 356 362 350 356 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig"><bold>Fig. 6</bold></xref>
###xml 709 710 697 698 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 703 710 691 698 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">Fig. 6<italic>B</italic></xref>
TGF-beta accumulation in valves has been linked to progression of valve fibrosis and subsequent calcification (3). In vitro, TGF-beta1 has been shown to up-regulate the contractile cytoskeleton of valve myofibroblasts and induce the formation of calcific nodules (1). These deleterious effects are attenuated by the addition of FGF-2, however. As shown in Fig. 6A, FGF-2 prevented, in a dose-dependent manner, TGF-beta1-mediated compaction (reduction of gel diameter) of collagen gels seeded with VICs. Moreover, fibrotic contraction was completely prevented when FGF-2 was supplied at a concentration of 100 ng/ml. Similarly, FGF-2 reduced TGF-beta1-mediated formation of calcific nodules. As shown in Fig. 6B, untreated control cultures formed no calcific nodules at the cell seeding densities tested; however, delivery of TGF-beta1 induced the formation of numerous calcium-containing nodules (50+/-5 nodules/well). Codelivery of FGF-2 (1-100 ng/ml) with TGF-beta1 significantly reduced the number of nodules that formed when compared with cultures that had been treated with TGF-beta1 alone.
###end p 41
###begin title 42
DISCUSSION
###end title 42
###begin p 43
###xml 405 409 395 399 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">(31)</xref>
###xml 522 526 512 516 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B34" ref-type="bibr">(34)</xref>
###xml 717 725 707 715 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5)</xref>
In this study, we show that FGF-2 serves as a potent inhibitor of TGF-beta1-mediated myofibroblast activation. Treatment of VIC cultures with FGF-2 inhibited activated alphaSMA expression, deposition of collagen matrix, fibrotic contractility, and calcified node formation. Although it has been reported that the actions of TGF-beta on myofibroblast development require the presence of mechanical tension (31), VICs have been recently shown to interact naturally with their matrix to significantly alter leaflet stiffness (34). While further investigation into the responses of VICs to these pharmacological stimuli under externally applied mechanical stress is warranted, our experiments with intact aortic leaflets (Fig. 5) suggest that FGF-2 signaling prevents myofibroblast differentiation in native, three-dimensional valve environments.
###end p 43
###begin p 44
###xml 575 579 569 573 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B35" ref-type="bibr">(35)</xref>
###xml 904 907 895 898 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">(22</xref>
###xml 907 911 898 902 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B36" ref-type="bibr">, 36</xref>
###xml 911 913 902 904 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B37" ref-type="bibr">37</xref>
###xml 913 915 904 906 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B38" ref-type="bibr">38</xref>
###xml 915 918 906 909 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B39" ref-type="bibr">39)</xref>
###xml 983 986 974 977 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B37" ref-type="bibr">(37</xref>
###xml 986 991 977 982 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B38" ref-type="bibr">, 38)</xref>
###xml 1063 1066 1054 1057 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">via</italic>
Our study implicates a distinct signaling pathway whereby FGF-2 acts to block Smad-mediated fibroblast activation through a MEK-ERK-dependent mechanism in valvular interstitial cells. By blocking the nuclear localization of Smads in response to TGF-beta1, FGF-2 effectively prevents Smad-dependent transcriptional activation of genes involved in the transition of VICs to a fibrotic phenotype. Many studies have demonstrated that there is significant intracellular crosstalk between MEK-ERK and TGF-beta1; however, modulation of Smad activity by MAPKs is cell-type dependent (35). In our work with VICs, however, we see that blocking MEK activity with the pharmacological inhibitor U0126 abrogates the ability of FGF-2 to block TGF-beta1-mediated fibrosis, suggesting that the MAPKs are involved in regulating Smad activity in these cells. Several reports indicate that Smads are phosphorylated by MAPKs (22, 36373839), such as phosphorylation of the linker region of R-Smads by ERK (37, 38), leading us to believe that MAPKs alter Smad activity and localization via direct interactions in the cytoplasm.
###end p 44
###begin p 45
###xml 1011 1015 993 997 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B40" ref-type="bibr">(40)</xref>
The antagonistic function of FGF-2 and TGF-beta1 on Smad activity and nuclear localization in valve myofibroblasts reported here demonstrates that Smad activity is controlled by a delicate balance of signaling emanating from receptor tyrosine kinases and serine/threonine receptor kinases. These data can be assimilated into a working model of myofibroblast differentiation resulting from competing inputs of TGF-beta and FGF signaling. In this model, basal activation of MAPK by FGF-2 is an important antagonistic checkpoint for regulation of TGF-beta signals. Furthermore, inhibition of FGF/MAPK signaling creates a permissive environment for enhanced TGF-beta activity. Collectively, this model suggests that reduction of MAPK activation induces myofibroblast activation and progression of myofibroblast-related fibrotic pathologies in an analogous manner to TGF-beta1 over-expression. Although our data indicate that MEK activity is important for FGF-2 to repress TGF-beta1-mediated fibrosis, other reports (40) have shown that activation of ERK activity by hepatocyte growth factor and epidermal growth factor also suppresses myofibroblast differentiation, suggesting that multiple stimuli work through this central MAPK-Smad pathway.
###end p 45
###begin p 46
The identification of critical regulatory pathways that control fibrosis is of profound importance to the fields of tissue engineering and medicine. By identifying a signaling pathway that acts to oppose myofibrotic differentiation, the work presented here extends our understanding of the role of FGF-2 in controlling cell fate decisions and provides insight into the management of the myofibroblast phenotype. Controlling fibrotic differentiation is crucial to engineering applications that hope to create tissue replacements of damaged heart valves. Armed with an improved understanding of the mechanisms that control cell growth and differentiation, engineers will be better prepared to design and manage the cellular environments that promote the development of normal tissues. Moreover, the identification of pathways that regulate myofibrotic differentiation will be essential to the development of improved therapeutic strategies for combating fibrotic lesions in the heart valve, as well as other tissues known to be affected by the enduring presence of matrix-synthesizing myofibroblasts.
###end p 46
###begin p 47
Funding for this project was provided by the Howard Hughes Medical Institute and a grant from the American Heart Association (0355488Z), as well as fellowships to M.C.C. from the Department of Education Graduate Assistance in Areas of National Need (GAANN) and NIH Leadership Training in Pharmaceutical Biotechnology to J.T.L. and to E.A.S. from the University of Colorado's Undergraduate Research Opportunity Program, Bioscience Undergraduate Research Skills and Training Biological Sciences Initiative, and Discovery Learning Center Apprenticeship.
###end p 47
###begin article-title 48
Valvular myofibroblast activation by transforming growth factor-beta
###end article-title 48
###begin article-title 49
###xml 69 74 <span type="species:ncbi:9606">human</span>
Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification
###end article-title 49
###begin article-title 50
###xml 149 152 149 152 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">via</italic>
Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis
###end article-title 50
###begin article-title 51
Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar
###end article-title 51
###begin article-title 52
Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves
###end article-title 52
###begin article-title 53
Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves
###end article-title 53
###begin article-title 54
###xml 89 94 <span type="species:ncbi:9606">human</span>
Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia
###end article-title 54
###begin article-title 55
Hepatic stellate cells: unique characteristics in cell biology and phenotype
###end article-title 55
###begin article-title 56
Role of myofibroblasts during normal tissue repair and excessive scarring: interest of their assessment in nephropathies
###end article-title 56
###begin article-title 57
Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis
###end article-title 57
###begin article-title 58
Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury
###end article-title 58
###begin article-title 59
The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta 1
###end article-title 59
###begin article-title 60
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy
###end article-title 60
###begin article-title 61
Therapeutic strategies to halt renal fibrosis
###end article-title 61
###begin article-title 62
Fibrogenesis:V. TGF-beta signaling pathways
###end article-title 62
###begin article-title 63
TGF-beta signaling and the fibrotic response
###end article-title 63
###begin article-title 64
Alpha-smooth muscle actin expression upregulates fibroblast contractile activity
###end article-title 64
###begin article-title 65
FGF-2 antagonizes the TGF-beta1-mediated induction of pericyte alpha-smooth muscle actin expression: a role for myf-5 and Smad-mediated signaling pathways
###end article-title 65
###begin article-title 66
Fibroblast growth factor reversal of the corneal myofibroblast phenotype
###end article-title 66
###begin article-title 67
###xml 139 144 <span type="species:ncbi:9606">human</span>
Transforming growth factor beta 1 and interleukin 4 induced alpha smooth muscle actin expression and myofibroblast-like differentiation in human synovial fibroblasts in vitro: modulation by basic fibroblast growth factor
###end article-title 67
###begin article-title 68
FAK-dependent regulation of myofibroblast differentiation
###end article-title 68
###begin article-title 69
A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras
###end article-title 69
###begin article-title 70
How cells read TGF-beta signals
###end article-title 70
###begin article-title 71
Porcine cardiac valvular subendothelial cells in culture: cell isolation and growth characteristics
###end article-title 71
###begin article-title 72
Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 interactions with matrix molecules
###end article-title 72
###begin article-title 73
###xml 130 134 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Extracellular matrix: differential influence on growth and biosynthesis patterns of vascular smooth muscle cells from SHR and WKY rats
###end article-title 73
###begin article-title 74
Specificity in transforming growth factor beta-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor muE3, and Smad proteins
###end article-title 74
###begin article-title 75
Image Processing with ImageJ
###end article-title 75
###begin article-title 76
###xml 67 72 <span type="species:ncbi:9606">human</span>
Identification and characterization of calcifying valve cells from human and canine aortic valves
###end article-title 76
###begin article-title 77
Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle
###end article-title 77
###begin article-title 78
Myofibroblasts and mechano-regulation of connective tissue temodelling
###end article-title 78
###begin article-title 79
TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing
###end article-title 79
###begin article-title 80
Cellular signaling by fibroblast growth factor receptors
###end article-title 80
###begin article-title 81
The effects of cellular contraction on aortic valve leaflet flexural stiffness
###end article-title 81
###begin article-title 82
Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis
###end article-title 82
###begin article-title 83
Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3
###end article-title 83
###begin article-title 84
Integration of Smad and MAPK pathways: a link and a linker revisited
###end article-title 84
###begin article-title 85
Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1
###end article-title 85
###begin article-title 86
Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases
###end article-title 86
###begin article-title 87
Hepatocyte Growth Factor Suppresses Renal Interstitial Myofibroblast Activation and Intercepts Smad Signal Transduction
###end article-title 87
###begin p 88
###xml 59 60 59 60 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 101 103 101 103 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">II</italic>
###xml 188 189 184 185 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 272 275 267 270 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">III</italic>
###xml 309 311 304 306 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IV</italic>
###xml 325 326 320 321 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 360 367 355 362 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">de novo</italic>
###xml 566 569 556 559 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
###xml 685 686 671 672 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 949 950 931 932 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1062 1063 1044 1045 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1127 1128 1109 1110 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1261 1262 1243 1244 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1594 1595 1576 1577 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1595 1596 1577 1578 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1607 1608 1589 1590 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
FGF-2 reduced markers of myofibroblast activation in VICs. A) Treatment of VICs with 10 ng/ml FGF-2 (II) reduced alphaSMA expression when compared with untreated control cell populations (I). Inhibition of FGF signaling with 50 mug/ml of antibodies that neutralize FGF-2 (III) or the FGF-2 receptors, FGFR-2 (IV) and FGFR-3 (V), caused a dramatic induction of de novo alphaSMA expression (green). Counterstaining of nucleic acid with propidium iodide is shown in red. All images were taken at the same magnification; scale bar = 10 mum. Previously published studies (1) have demonstrated the efficacy of the anti-alphaSMA antibody to selectively stain stress fibers in myofibroblasts. B) Dose-dependent reduction of alphaSMA expression by FGF-2 in VICs. VICs were incubated for 48 h with FGF-2 at the concentrations indicated, and expression was detected by cell-based ELISA. Expression is shown as a percentage of the untreated (0 ng/ml) controls. C) Dose-dependent reduction in matrix deposition by FGF-2 in VICs. VICs were incubated for 72 h with FGF-2, and [3H]proline incorporation was measured by scintillation counter. [3H]proline levels were normalized to DNA content of each sample to account for potential differences in cell numbers between samples. D) Cell growth is unaffected by FGF-2. Subconfluent VIC cultures were treated with FGF-2 for 72 h, and the relative number of cells in each sample was determined by measuring total dsDNA content. In all charts, the dashed line indicates the level of untreated controls and represents the level to which treated samples are compared. #P < 0.05; **P < 0.001.
###end p 88
###begin p 89
###xml 66 67 63 64 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 366 369 349 352 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">. B</italic>
###xml 548 549 525 526 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 618 619 595 596 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 752 753 729 730 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1561 1562 1515 1516 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1562 1563 1516 1517 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1573 1574 1527 1528 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
FGF-2 blocks TGF-beta1-mediated myofibroblast activation in VICs. A) FGF-2 blocks the TGF-beta1-mediated induction of alphaSMA expression. VICs were incubated for 48 h with 5 ng/ml TGF-beta1 in combination with increasing concentrations of FGF-2, and alphaSMA expression was detected by cell-based ELISA. Expression is shown as a percentage of the untreated controls. B) FGF-2 blocks the TGF-beta1-mediated induction of matrix deposition. VICs were incubated for 72 h with 5 ng/ml TGF-beta1 in combination with increasing concentrations of FGF-2. [3H]proline incorporation was then measured by scintillation counter. [3H]proline levels were normalized to DNA content of each sample to account for potential differences in cell numbers between samples. C) FGF-2 blocks the TGF-beta1-mediated reduction in cell growth. Subconfluent VIC cultures were treated with 5 ng/ml TGF-beta1 in combination with increasing concentrations of FGF-2. After 72 h, the relative number of cells in each sample was determined by measuring total dsDNA content. Normal culturing conditions for VICs represses alphaSMA expression even though TGF-beta signaling appears active. VICs were incubated for 48 h in either serum-free media or treated with an anti-TGF-beta neutralizing antibody, and alphaSMA expression was detected by cell-based ELISA. Expression is shown as a percent of the controls cultured in 15% FBS. In all charts, the dashed line indicates the level of untreated controls (0 ng/ml TGF-beta1 and FGF-2) and represents the level to which treated samples are compared. #P < 0.05; *P < 0.01.
###end p 89
###begin p 90
###xml 58 59 55 56 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 609 610 594 595 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 721 723 703 705 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">II</italic>
###xml 746 749 725 728 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">III</italic>
###xml 761 763 740 742 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IV</italic>
###xml 1181 1182 1156 1157 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1182 1183 1157 1158 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
TGF-beta1-stimulated Smad activity is modulated by FGF-2. A) FGF-2 blocks TGF-beta1-mediated transcriptional induction of Smad-responsive promoter. VICs transfected with the Smad-responsive luciferase reporter plasmid PE2.1 were treated with increasing concentrations of FGF-2 and luciferase activity was measured after 48 h. TGF-beta1 (5 ng/ml) caused a 3.5-fold increase in luciferase activity when compared with untreated controls. This increase is markedly attenuated when FGF-2 (1-100 ng/ml) is codelivered with TGF-beta1. Dashed line indicates level of untreated controls (0 ng/ml TGF-beta1 and FGF-2). B) FGF-2 blocks TGF-beta1-mediated Smad-3 nuclear accumulation in VICs. VICs were treated with FGF-2 (10 ng/ml; II), TGF-beta1 (5 ng/ml; III), or both (IV). Representative micrographs show cellular localization of Smad-3 by indirect immunoperoxidase staining. VICs treated with TGF-beta1 alone showed increased nuclear staining, indicating that Smad-3 had been translocated to the nucleus in these cells. FGF-2 treated cells have cytoplasmic staining with obvious occlusion of Smad-3 from the nucleus. All images were taken at the same magnification. Scale bar = 2.5 mum. #P < 0.05.
###end p 90
###begin p 91
###xml 56 57 56 57 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 669 675 659 665 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Fig. 3</xref>
###xml 675 676 665 666 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 679 680 669 670 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1212 1218 1177 1183 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2</xref>
###xml 1218 1219 1183 1184 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1389 1390 1351 1352 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1390 1391 1352 1353 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
MAPK inhibitor blocks myofibroblast activation in VICs. A) The inhibition of ERK-1/2 prevents FGF-2 from blocking TGF-beta1-medaited Smad activation. VICs were transfected with the Smad-responsive luciferase reporter plasmid PE2.1 and treated with a combination of the MEK-1/2 inhibitor U0126 (15 mumol/L), FGF-2 (10 ng/ml), and/or TGF-beta1 (5 ng/ml). Luciferase activity was measured after 48 h after treatment. The MEK-1/2 inhibitor significantly increases Smad activity when compared with untreated controls. Moreover, U0126 prevented FGF-2 from reducing the TGF-beta1-mediated activation of the Smad-responsive promoter that was observed in a previous experiment (Fig. 3A). B) The inhibition of ERK-1/2 prevents FGF-2 from blocking the TGF-beta1-medaited induction of alphaSMA expression. VICs were treated with a combination of the MEK-1/2 inhibitor U0126 (15 mol/L), FGF-2 (10ng/ml), and/or TGF-beta1 (5 ng/ml) for 48 h before alphaSMA detection by ELISA. The MEK-1/2 inhibitor U0126 significantly increased alphaSMA expression when compared with untreated controls. In addition, U0126 prevented FGF-2 from reducing the TGF-beta1-mediated induction of alphaSMA that was observed in a previous experiment (Fig. 2A). In each chart, the dashed line indicates the level of untreated controls (0 ng/ml TGF-beta1 and FGF-2) and represents the level to which treated samples are compared. #P < 0.05.
###end p 91
###begin p 92
###xml 223 224 219 220 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 244 246 240 242 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">II</italic>
###xml 269 272 262 265 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">III</italic>
###xml 295 297 287 289 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">IV</italic>
###xml 341 342 332 333 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 461 464 451 454 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
FGF-2 reduces fibrosis in intact aortic leaflets. alphaSMA expression in cultured porcine aortic valve leaflets is indicated by red immunoperoxidase staining. Intact valve leaflets were treated for 2 wk with control media (I), FGF-2 (10 ng/ml; II), TGF-beta1 (5 ng/ml; III), U0126 (15 mumol/L; (IV), or U0126 (15 mumol/L) + FGF-2 (10 ng/ml; V). All images were taken at the same magnification, and the scale bar is equal to 20 mum. Previously published studies (1) have demonstrated the efficacy of the anti-alphaSMA antibody to selectively stain stress fibers in myofibroblasts.
###end p 92
###begin p 93
###xml 75 76 72 73 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 520 521 508 509 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1008 1009 987 988 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1390 1391 1361 1362 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1391 1392 1362 1363 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1402 1403 1373 1374 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1414 1415 1385 1386 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
FGF-2 inhibits pathological phenotypes observed in TGF-beta1-treated VICs. A) FGF-2 prevents fibrotic contraction of VICs treated with TGF-beta1. VICs were encapsulated into 3-dimensional collagen matrices in 48-well tissue culture plates and treated with TGF-beta1 (5 ng/ml) and FGF-2 (0-100 ng/ml) for 24 h. Matrices were then detached from the plate surface, and gel surface area was determined using ImageJ software. Collagen gel areas are plotted as a percentage of untreated control (0 ng/ml TGF-beta1 and FGF-2). B) Dose-dependent reduction in TGF-beta1-mediated calcific nodule formation by FGF-2 in VICs. VICs were seeded into 96-well plates and treated with TGF-beta1 (5 ng/ml) and FGF-2 (0-100 ng/ml) for 72 h. The cells were then stained with Alizarin red to identify calcium-based mineralization, and the number of calcific nodules was counted in each well. No calcific nodules were observed in the untreated controls (0 ng/ml TGF-beta1 and FGF-2), which are represented as a dashed line on the x axis. However, VICs treated with TGF-beta1 showed a dramatic increase in nodule formation (>50 nodules/well), which is significantly attenuated by FGF-2 at concentrations >/=1 ng/ml. In each chart, the dashed line indicates the level of untreated controls (0 ng/ml TGF-beta1 and FGF-2) and represents the level to which treated samples are compared, unless indicated by brackets. #P < 0.05; *P < 0.01; **P < 0.001.
###end p 93

